Euroapi SAS (EAPI) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Euroapi SAS €1.26, price €0.77, upside +64.7%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Euroapi SAS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
53‑month range €0.7650 – €18.72 · fair‑value band €1.25 – €1.27 · the €0.7650 price screens below the €1.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Euroapi SAS in your weekly email
Every Wednesday you see whether Euroapi SAS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.
Show more
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Stock analysis
Euroapi SAS (EAPI) currently trades at €0.7650, while our model-based Fair Value estimate is €1.26, implying the stock looks roughly 39.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €6.22 per share, and 13 of the 13 models we run sit above the €0.7650 price.
Bear case: the Earnings-Based group reads lowest at €1.27, and 0 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: €1.25 (bear) to €1.27 (bull), the price of €0.7650 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Euroapi SAS reported revenue of €848M in FY2025 versus €893M in FY2021, a compound −1.3%/yr. Reported net income was −€211M in FY2025.
Key figures
Market cap €123M · P/S ratio 0.14 · EPS (TTM) €−2.23 · Net margin −24.9% · Return on equity −23.8% · Return on assets (EBIT) −4.5% · Operating margin −2.2% · Revenue (TTM) €853M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 65%, EAPI screens cheaper than that median.
Fair Value models
Bear €1.25Fair Value €1.26Bull €1.27
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.1% (2020) → 0.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside+59% · Top 25%
Profitability
Return on assets0% · Below median
Net margin (TTM)−25% · Bottom 25%
Operating margin (TTM)−2% · Bottom 25%
Growth and dividend
Revenue growth−6% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Euroapi SAS Fair Value". https://www.fairvalue-calculator.com/stock/EAPI
Frequently asked questions
Is Euroapi SAS (EAPI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €1.26 versus a price of €0.7650, about +65% upside (undervalued).
What is the fair value of EAPI?
Our model-based fair value for Euroapi SAS is €1.26 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.7650.
What is the quality score of EAPI?
Euroapi SAS has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Euroapi SAS (EAPI)?
Our model-based price target is the fair value of €1.26 (as of Sep 23, 2026) from 13 valuation models. Cautious scenario €1.25, optimistic scenario €1.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Euroapi SAS stock forecast for 2026?
Our models put fair value at €1.26, about +65% upside versus a price of €0.7650 (undervalued). Cautious scenario €1.25, optimistic scenario €1.27. The calculation is refreshed regularly with new filings.
What is the revenue of Euroapi SAS (EAPI)?
Euroapi SAS reported trailing-twelve-month revenue of about €853M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Euroapi SAS (EAPI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Euroapi SAS it is €1.26 per share (as of Sep 23, 2026), against a price of €0.7650. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Euroapi SAS stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EAPI trades below its calculated fair value: price €0.7650, fair value €1.26, a gap of about +65% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EAPI?
No. The price is what the market pays today (€0.7650); the fair value is what the company's own numbers justify (€1.26). For Euroapi SAS the two are €0.4950 per share apart. That gap is exactly why we show both numbers side by side.
How much is Euroapi SAS worth?
The market values Euroapi SAS at about €123M (market capitalisation, as of Sep 23, 2026). Per share that is €0.7650; our models calculate a fair value of €1.26 per share.
What do the bullish and bearish scenarios say about EAPI?
Our models span a range for Euroapi SAS: cautious scenario €1.25, base €1.26, optimistic €1.27 per share (as of Sep 23, 2026, price €0.7650). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Euroapi SAS (EAPI)?
Balance-sheet figures for Euroapi SAS (as of Sep 23, 2026): return on equity −23.8%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is EAPI from its 52-week high?
Euroapi SAS trades at €0.7650, about 77% below its 52-week high of €3.36 and at the low of €0.7650 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €1.26 is for.
Which stocks are comparable to Euroapi SAS?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Euroapi SAS stock attractive at the current price?
The data as of Sep 23, 2026: price €0.7650, calculated fair value €1.26 (+65%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EAPI calculated?
We run Euroapi SAS through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €1.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Euroapi SAS currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Euroapi SAS (EAPI)?
The closing price on Sep 24, 2026 was €0.7650. Our model-based fair value is €1.26, about +65% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Euroapi SAS right now?
The price is below even our cautious bear case (€1.25). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band (€1.25 to €1.27), unusually little disagreement for a valuation.
Key figures of Euroapi SAS
How large is the market capitalisation of Euroapi SAS (EAPI)?
The market capitalisation of Euroapi SAS is €123M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Euroapi SAS (EAPI)?
The price-to-sales ratio of Euroapi SAS is 0.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Euroapi SAS (EAPI)?
Earnings per share at Euroapi SAS are €−2.23. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Euroapi SAS (EAPI)?
The net margin of Euroapi SAS is −24.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Euroapi SAS (EAPI)?
The return on equity (ROE) of Euroapi SAS is −23.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Euroapi SAS (EAPI)?
On an EBIT basis the return on assets of Euroapi SAS is −4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Euroapi SAS (EAPI)?
The operating margin of Euroapi SAS is −2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Euroapi SAS (EAPI)?
Revenue at Euroapi SAS is growing −6.4% versus a year earlier (3y avg −4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Euroapi SAS (EAPI)?
Earnings per share at Euroapi SAS are growing +267% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Euroapi SAS (EAPI) generate?
The free cash flow of Euroapi SAS is €47.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Euroapi SAS (EAPI) hold?
Euroapi SAS holds more cash than debt, €48.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Euroapi SAS in the live analysis
One click puts Euroapi SAS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
